Breast implant revision: How much does breast implant revision cost?

This lender-commissioned benchmark reports $7,986 and $5,397 to $13,533, with sample size and complete fee/device inclusions unspecified.

ASPS’s separate removal page says “average cost of breast implant removal surgery is $3,979”, excluding anesthesia, operating room and related expenses. Checked October 13, 2026, with data year unstated; this cannot price replacement.

Heavenly’s $10,750 promotional floor has no printed expiration or established major-fee/device inclusions. Request a dated complete quote.

Gandolfi’s breast fat-transfer floor is $3,000 surgeon-only, not a revision total. The research has no isolated complete own-fee operation specifically priced as revision fat grafting; ask about harvesting, facility time and staging.

Mundra’s Denver floor and Boulder’s range describe area prices, not their own fees. They never enter the opening statistic.

Ask about follow-up and problems after traveling home. These records give no standard airfare, hotel, child-care or lost-wage allowance; budget your own costs.

The aggregate removal range repeats the detailed endpoints, not an independent practice or bill. The printed city is Layton.

Aesthetica starts removal without capsulectomy at $3,900 and with capsulectomy at $6,900, including major surgical fees. Neither floor establishes replacement, lift or a maximum.

Natrelle’s 04/24 brochure and live summary, checked October 13, 2026, distinguish lifetime qualifying-rupture replacement for affected and contralateral implants from up to $3,500 out-of-pocket assistance for 10 years. Device replacement does not pay the whole operation. Applicable original terms still matter.

For Baker III/IV contracture, replacement is listed for 10 years. Augmentation cash assistance is up to $2,000 for 2 years, one incident per patient; the recurring-contracture footnote limits that benefit. Qualifying textured late-seroma replacement is 20 years, with up to $1,000 diagnostic testing to rule out BIA-ALCL. The source excludes prior textured implants exchanged to smooth from this late-seroma provision.

Standard saline coverage gives qualifying lifetime device replacement. Premier costs $200 within 45 days and lists up to $2,400 out-of-pocket deflation assistance for 10 years. Late enrollment is reviewed case by case. Saline contracture is not covered. Qualifying saline-to-gel replacement offers Responsive gel without a product upgrade charge; SoftTouch or Cohesive costs $100 per implant, separate from surgery.

The surgeon contacts Product Surveillance before surgery and returns disinfected explants within 3 months with required records and authorizations. The summary says lifetime BIA-ALCL replacement and up to $7,500 treatment assistance; the brochure limits expenses to implant removal and associated scar-tissue removal, complete capsulectomy, and does not separately print a lifetime BIA-ALCL duration. It does not fund all oncology care. Intact aesthetic changes and procedure-related damage are excluded.

For implantation on or after January 1, 2021, qualifying rupture gets lifetime replacement, at most 2 implants with a MENTOR contralateral device, and up to $3,500 aggregate unreimbursed replacement-surgery assistance for 10 years. Operating room and anesthesia take payment priority. Earlier implantation periods retain their original warranty. The free Basic plan is automatic.

Basic gel assistance for Baker III/IV contracture is up to $2,000 for 2 years without prior contracture. Device replacement for qualifying contracture, double capsule and late seroma is listed for 10 years. Enhanced costs $300 within 45 days and lists up to $3,500 for qualifying nonrupture events for 10 years. Prior Baker I–IV contracture excludes Enhanced eligibility; it does not exclude every Basic rupture payment. Basic and Enhanced cash are not stacked for simultaneous events.

Free saline coverage provides lifetime qualifying-deflation replacement, without a listed included surgical cash benefit. Saline Enhanced costs $200 within 45 days and lists up to $2,400 uncovered replacement-surgery assistance for 10 years. The full contract’s saline-to-MemoryGel upgrade is $250 per requested product; this is a device upgrade charge, not a revision fee.

The maker-linked US gel and saline contracts, checked October 13, 2026, require eligible procurement, physicians, event evidence, bills, insurance forms and product-release authorization. Ruptured/deflated products must be returned within 60 days. Ineligible Enhanced enrollment has a refund clause denying listed nonrupture benefits, so do not assume device eligibility despite that clause. Intact size changes, rippling and specified procedure damage are excluded. MemoryGel Enhance used for augmentation is outside this Promise plan.

Sientra’s LGL-0006-R7 applies to eligible US/Puerto Rico implants placed on or after May 1, 2018. Qualifying rupture has lifetime device replacement and one-time assistance up to $5,000 for actual eligible uncovered costs within 20 years. Earlier surgeries have separate documents. The upload path does not establish an effective date; the R7 issue date is not printed.

Qualifying Baker III/IV contracture, double capsule, late seroma and BIA-ALCL have 20-year device replacement. Contracture/double capsule/late-seroma cash is one-time up to $2,000 within 2 years. Contracture must form at least 3 months after surgery; qualifying late seroma is at least 12 months. BIA-ALCL assistance is up to $7,500 within 20 years, inclusive of eligible testing. Only the highest applicable benefit is paid for one surgery; the amounts are not additive.

The surgeon completes tracking/enrollment within 60 days, initiates preauthorization before revision/explant, and returns products and documentation within 30 days after explant. The contract requires a licensed plastic surgeon who is board-certified or board-admissible, documentation of actual uncovered expenses and a liability release. It excludes size/style changes, rippling, specified procedure damage, lost wages and pain/suffering.

The contract broadly excludes events or injury reimbursed by insurance or with any provider fees waived, while its financial section describes remaining unpaid/nonpayable costs. The brochure simplifies this to uncovered fees. Ask the program to determine eligibility in an insured or partly waived case; neither the headline cap nor enrollment settles your payment.

The currently linked July 2025 US contract applies to implantation on or after September 26, 2024. Included enrollment is automatic; confirm surgeon-uploaded implant details and registration email. Qualifying rupture/BIA-ALCL device replacement is lifetime; qualifying contracture/double capsule/late-seroma device replacement is 10 years. Rupture assistance is up to $3,500 once within 10 years; Baker III/IV assistance is up to $2,000 once within 2 years. The base BIA-ALCL benefit is lifetime, up to $7,500, with a $7,500 per-surgery maximum.

Plus requires registration and a one-time $250 payment within 90 days. Rupture assistance is up to $5,000 once within 10 years. Contracture assistance is up to $2,500 within 2 years for revision augmentation; the 5-year branch is primary augmentation. Late-seroma assistance is up to $2,000 and double-capsule assistance up to $3,500, each within 2 years. Plus BIA-ALCL assistance is up to $15,000 through 10 years and up to $7,500 from year 11 onward; the maximum per qualifying surgery is $15,000.

The live Plus headline groups late seroma/double capsule at $3,500 and describes 5-year contracture assistance. Its lower table and July 2025 contract separate late seroma at $2,000 and revision contracture at 2 years. Both statements remain visible here. Plus device replacement is lifetime except qualifying contracture, which is 10 years. The contract requires preauthorization, a release and device/document return within 30 days. Prior non-Motiva contracture excludes the revision contracture-event claim; prior textured implants exclude the BIA-ALCL-event claim, not every event.

Bimini’s Serene IFU describes conditional lifetime replacement for qualifying implant failure. The retrieved warranty card gives no surgical-assistance amount or enrollment deadline; that is missing information, not zero. The historical IDEAL July 1, 2015 contract, applicable from August 1, 2015, lists up to $2,400 aggregate eligible uninsured replacement-surgery costs within 10 years. Bimini’s asset acquisition does not establish current honoring of every legacy liability. Obtain a written answer for the original device.

Ask which modality is appropriate and request ordering, imaging and interpretation charges. FDA gives timing guidance, not a dollar estimate. Its things-to-consider page says regular MRI/ultrasound exams may not be covered by insurance.

FDA identifies persistent swelling, a mass or pain near an implant as symptoms to discuss with your treating clinician. ASPS describes evaluation of fluid or a mass before routine revision planning. Contact the treating team for assessment; a price comparison cannot identify rupture, contracture or an implant-associated malignancy.

Implant age, warranty windows and screening intervals are different dates. Ask what finding or personal goal supports surgery and what future surveillance remains.

Aetna’s removal branches include silicone rupture, extrusion, recurrent infection, painful Baker IV and severe contracture interfering with mammography. Baker III outside reconstruction needs medical review. Reinsertion after originally cosmetic implantation is “cosmetic” despite medically necessary removal. Saline rupture alone does not qualify. Contralateral removal qualifies when one side meets criteria.

Cigna requires imaging for silicone rupture. Other removal branches include Baker IV, exposure, necrosis, malignancy and BIOCELL; infection needs failed/contraindicated/intolerable medical treatment. Cosmetic replacement and mastopexy are “not medically necessary/cosmetic” outside reconstruction exceptions. Contralateral removal ordinarily must independently qualify; shifting/appearance alone is excluded.

Commercial/Individual Exchange MP.007.33, effective June 1, 2026, calls leaking/defective silicone removal covered, with replacement only after reconstructive original placement. Breast Reconstruction MP.003.29 separately allows BIOCELL removal regardless of original indication and refers other removal/capsule work to InterQual. Complete criteria were not retrieved; no contracture threshold is inferred.

Anthem’s removal branches include documented silicone rupture, infection, exposure/extrusion, painful Baker IV, BIOCELL and removal before breast-cancer surgical treatment. Cosmetic-origin reimplantation is “cosmetic and not medically necessary” outside disease/deformity/reconstruction exceptions. Repositioning and mastopexy are cosmetic outside covered reconstruction; saline rupture alone does not qualify.

JE/JF includes Utah, Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, North Dakota, Oregon, South Dakota, Washington, Wyoming and listed Pacific territories. Removal branches include failed implant, infection, extrusion, siliconoma/granuloma, cancer-diagnosis interference and painful disfiguring contracture after cosmetic or reconstructive implantation. This does not establish new cosmetic replacement benefits. Ask about local billing article A57221.

South Carolina HUM-2030-001, effective September 3, 2025, has a noncosmetic-original branch plus separate BIA-ALCL/BIOCELL/BIA-SCC provisions. Refractory-infection proof permits aspirate evidence or listed clinical symptoms; qualifying reinsertion may be covered. Louisiana LA.CLI.040.001, effective May 18, 2026, lists nonreconstructive removal, including suspected/diagnosed rupture and visible painful Baker IV, without South Carolina’s original-implant prerequisite. Contralateral removal may qualify; general cosmetic replacement is not established.

This specific brochure excludes surgery primarily to improve appearance except stated accidental-injury/reconstructive provisions. It says preauthorization does not establish coverage. The provider portal uses InterQual where a policy is unavailable; complete revision criteria were not retrieved. These are not rules for every Select Health product.

The clinical recheck recovered Surgery 40 despite the price-pass catalog gap. Reconstructive implant benefits require a reconstructive original indication; pathologically confirmed BIA-ALCL/BIA-SCC has a separate explantation branch. Its cosmetic-primary clause says cosmetic when “one or more of Criteria I, II, III, or IV is not met”. Member contracts take precedence.

The clinical recheck’s Section 9.18 of the 2026 Individual EPO, effective January 1, 2026, excludes capsule procedures, replacement, removal or repair of originally cosmetic implants, with reconstructive exceptions to read in context. The price-pass 2024 document stays historical; neither establishes every university/employer product’s benefits.

The April 2026 breast-surgery preauthorization form lists removal, reimplantation and capsule procedures, but a selectable procedure is not a benefit. The July 2026–June 2027 State guide does not supply complete implant-revision criteria; members must obtain the applicable Master Policy. The price pass’s 2018–19 exclusion stays historical. Policy text is not a coverage guarantee.

Request the benefit determination, allowed services, network status and patient responsibility for surgeon, facility, anesthesia, pathology and devices. Get any cosmetic portion quoted separately. The patient-source corpus contains no complete US approval/denial and final net bill that settles these questions for another person. Policy text is not a coverage guarantee.

CareCredit’s factors round payments upward to whole dollars with possibly smaller final payments. Payment times term is an upper bound. These amortizations do not replace your contract.

CareCredit and CFPB explain that interest accrues from the purchase date and can be charged if a promotional balance is not cleared under the agreement. Minimum payments may not clear it by the deadline. Cherry’s separate waived-interest promotion requires full principal/fee payoff and every payment within 15 days of its due date; its true-zero blog does not override that disclosure.

The corpus has no complete US warranty claim and bridging-loan history. Ask who pays first, who receives reimbursement and what delays cost; unconfirmed assistance cannot reduce the payable bill.

$18,500. exchange, internal mesh and lift described also as pocket work; implant/device and anesthesia inclusions unstated. patient-reported; no bill verified; not found. Device, facility and anesthesia inclusions must be confirmed rather than inferred from the operation name.

$14,000. exchange from silicone to larger saline implants with donut lift; other inclusions not stated. patient-reported; no bill verified; not found. Device, facility and anesthesia inclusions must be confirmed rather than inferred from the operation name.

$14,000. planned repeat exchange/upsize with Strattice mesh; not the earlier lift bill. patient-reported; no bill verified; not found. Device, facility and anesthesia inclusions must be confirmed rather than inferred from the operation name.

Claire’s expected assistance is not confirmed paid and the manufacturer is not identified. Her same-size plan does not establish whether new devices were purchased or supplied. This is one patient’s quote and anticipated reimbursement, not a warranty approval, insurance decision or a fee offered to another patient.